Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 13 | 2020 | 78 | 3.220 |
Why?
|
| Chickens | 10 | 2020 | 33 | 1.260 |
Why?
|
| Autoantibodies | 5 | 2016 | 63 | 1.130 |
Why?
|
| Ovary | 7 | 2013 | 22 | 1.020 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 200 | 0.870 |
Why?
|
| Disease Models, Animal | 9 | 2013 | 529 | 0.830 |
Why?
|
| Antibodies, Neoplasm | 3 | 2009 | 11 | 0.780 |
Why?
|
| Selenium-Binding Proteins | 2 | 2016 | 2 | 0.780 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2016 | 8 | 0.650 |
Why?
|
| Infertility, Female | 2 | 2016 | 19 | 0.650 |
Why?
|
| Inflammasomes | 1 | 2020 | 9 | 0.620 |
Why?
|
| Antigens, Neoplasm | 3 | 2009 | 41 | 0.560 |
Why?
|
| Endometriosis | 1 | 2016 | 15 | 0.500 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 7 | 0.500 |
Why?
|
| Follicle Stimulating Hormone | 5 | 2008 | 22 | 0.460 |
Why?
|
| Menopause | 5 | 2008 | 100 | 0.450 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2013 | 4 | 0.400 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2013 | 4 | 0.400 |
Why?
|
| Ovarian Follicle | 4 | 2009 | 11 | 0.400 |
Why?
|
| Female | 23 | 2020 | 13153 | 0.400 |
Why?
|
| Animals | 11 | 2020 | 3304 | 0.400 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 49 | 0.400 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 94 | 0.380 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 111 | 0.370 |
Why?
|
| Humans | 21 | 2020 | 23217 | 0.280 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 135 | 0.250 |
Why?
|
| RNA, Messenger | 3 | 2020 | 283 | 0.230 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 52 | 0.230 |
Why?
|
| Adult | 12 | 2016 | 6964 | 0.220 |
Why?
|
| Neoplasm Staging | 5 | 2013 | 353 | 0.210 |
Why?
|
| Corpus Luteum | 2 | 2004 | 5 | 0.200 |
Why?
|
| Pain | 1 | 2006 | 332 | 0.200 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 93 | 0.200 |
Why?
|
| Muscle, Skeletal | 1 | 2006 | 341 | 0.190 |
Why?
|
| Estradiol | 1 | 2002 | 52 | 0.190 |
Why?
|
| Inflammation | 3 | 2020 | 231 | 0.180 |
Why?
|
| Receptors, Gonadotropin | 1 | 2001 | 2 | 0.170 |
Why?
|
| Granulosa Cells | 1 | 2001 | 5 | 0.170 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2014 | 220 | 0.160 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 339 | 0.160 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2020 | 7 | 0.160 |
Why?
|
| Middle Aged | 9 | 2016 | 7983 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 57 | 0.150 |
Why?
|
| Menopause, Premature | 1 | 1999 | 7 | 0.150 |
Why?
|
| Cytokines | 1 | 2020 | 192 | 0.140 |
Why?
|
| Immunoassay | 2 | 2009 | 33 | 0.140 |
Why?
|
| ROC Curve | 1 | 2016 | 122 | 0.120 |
Why?
|
| Menstrual Cycle | 2 | 2007 | 19 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2016 | 486 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 3866 | 0.110 |
Why?
|
| Warfare | 1 | 2014 | 12 | 0.110 |
Why?
|
| Terrorism | 1 | 2014 | 9 | 0.110 |
Why?
|
| Cytomegalovirus | 1 | 2014 | 15 | 0.110 |
Why?
|
| Adolescent | 2 | 2016 | 1884 | 0.100 |
Why?
|
| Young Adult | 2 | 2016 | 1659 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 48 | 0.100 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 16 | 0.100 |
Why?
|
| Violence | 1 | 2013 | 35 | 0.100 |
Why?
|
| Estrone | 3 | 2008 | 8 | 0.090 |
Why?
|
| Pregnanediol | 3 | 2008 | 7 | 0.090 |
Why?
|
| Luteinizing Hormone | 3 | 2008 | 12 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2014 | 215 | 0.090 |
Why?
|
| Follicular Fluid | 2 | 2002 | 8 | 0.090 |
Why?
|
| Fluorocarbons | 1 | 2011 | 11 | 0.080 |
Why?
|
| Albumins | 1 | 2011 | 18 | 0.080 |
Why?
|
| Image Enhancement | 1 | 2011 | 42 | 0.080 |
Why?
|
| Aged | 2 | 2016 | 7664 | 0.080 |
Why?
|
| Flax | 1 | 2010 | 1 | 0.080 |
Why?
|
| Ultrasonography, Doppler | 1 | 2010 | 11 | 0.080 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2010 | 16 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 35 | 0.080 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2009 | 7 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2011 | 204 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 15 | 0.070 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 15 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 25 | 0.070 |
Why?
|
| Algorithms | 1 | 2011 | 305 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2009 | 23 | 0.070 |
Why?
|
| Cyclooxygenase 1 | 1 | 2008 | 6 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 29 | 0.070 |
Why?
|
| Luteal Phase | 1 | 2008 | 5 | 0.070 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2007 | 2 | 0.070 |
Why?
|
| Pulsatile Flow | 1 | 2007 | 4 | 0.070 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2007 | 6 | 0.070 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 17 | 0.070 |
Why?
|
| Ovarian Cysts | 1 | 2007 | 4 | 0.070 |
Why?
|
| Vascular Resistance | 1 | 2007 | 12 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 51 | 0.060 |
Why?
|
| Disease Progression | 1 | 2009 | 547 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 132 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2007 | 210 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 1 | 2006 | 45 | 0.060 |
Why?
|
| Cross-Cultural Comparison | 1 | 2006 | 37 | 0.060 |
Why?
|
| Logistic Models | 1 | 2006 | 357 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 1431 | 0.060 |
Why?
|
| Random Allocation | 2 | 2010 | 102 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2006 | 179 | 0.060 |
Why?
|
| Pain Measurement | 1 | 2006 | 412 | 0.050 |
Why?
|
| United States | 2 | 2006 | 1804 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 778 | 0.050 |
Why?
|
| Inhibins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Androstenedione | 1 | 2002 | 4 | 0.050 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2002 | 5 | 0.050 |
Why?
|
| Ovulation Induction | 1 | 2002 | 10 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 10 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 14 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 11 | 0.050 |
Why?
|
| Fertilization in Vitro | 1 | 2002 | 13 | 0.050 |
Why?
|
| Progesterone | 1 | 2002 | 19 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2002 | 45 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 45 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 70 | 0.050 |
Why?
|
| Receptors, LH | 1 | 2001 | 2 | 0.040 |
Why?
|
| CHO Cells | 1 | 2001 | 10 | 0.040 |
Why?
|
| Cricetinae | 1 | 2001 | 33 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2001 | 100 | 0.040 |
Why?
|
| Risk Factors | 1 | 2006 | 2021 | 0.040 |
Why?
|
| Depression | 2 | 2014 | 383 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2014 | 381 | 0.040 |
Why?
|
| Cardiolipins | 1 | 1999 | 2 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 1999 | 4 | 0.040 |
Why?
|
| Blood Donors | 1 | 1999 | 5 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 446 | 0.040 |
Why?
|
| Causality | 1 | 1999 | 44 | 0.040 |
Why?
|
| Thyroid Gland | 1 | 1999 | 43 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 1999 | 73 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 599 | 0.040 |
Why?
|
| Aging | 2 | 2003 | 1180 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2006 | 2994 | 0.030 |
Why?
|
| Cognition | 1 | 2003 | 1026 | 0.030 |
Why?
|
| Israel | 1 | 2014 | 11 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2014 | 39 | 0.030 |
Why?
|
| Crime Victims | 1 | 2013 | 23 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 9 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 59 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2004 | 1106 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2004 | 1467 | 0.020 |
Why?
|
| Diet | 1 | 2010 | 181 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 1037 | 0.020 |
Why?
|
| Ovulation | 1 | 2008 | 3 | 0.020 |
Why?
|
| Oviposition | 1 | 2008 | 2 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2008 | 1 | 0.020 |
Why?
|
| European Continental Ancestry Group | 1 | 2008 | 2 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 112 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 144 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 19 | 0.020 |
Why?
|
| Body Constitution | 1 | 2004 | 3 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 69 | 0.010 |
Why?
|
| Postmenopause | 1 | 2003 | 57 | 0.010 |
Why?
|
| Income | 1 | 2003 | 67 | 0.010 |
Why?
|
| Women's Health | 1 | 2004 | 174 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 269 | 0.010 |
Why?
|
| Educational Status | 1 | 2003 | 223 | 0.010 |
Why?
|
| Memory | 1 | 2003 | 225 | 0.010 |
Why?
|
| Chicago | 1 | 2003 | 848 | 0.010 |
Why?
|
| Male | 1 | 2014 | 12667 | 0.010 |
Why?
|